Clinical Trials
250
Active:12
Completed:25
Trial Phases
6 Phases
Early Phase 1:9
Phase 1:48
Phase 2:107
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (225 trials with phase data)• Click on a phase to view related trials
Phase 2
107 (47.6%)Phase 1
48 (21.3%)Not Applicable
43 (19.1%)Phase 4
13 (5.8%)Early Phase 1
9 (4.0%)Phase 3
5 (2.2%)A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Phase 2
Not yet recruiting
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Target Recruit Count
- 134
- Registration Number
- NCT07034508
- Locations
- 🇨🇳
China Institute of Hematology and Blood Diseases Hospital, Tianjin, China
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Recruiting
- Conditions
- T-LGL LeukemiaNK-LGL Leukemia
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 9999
- Registration Number
- NCT07019766
- Locations
- 🇨🇳
Red Blood Cell Diseases Center and Regenerative Medicine Center, Tianjin, Tianjin, China
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Recruiting
- Conditions
- AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia Mixed Type
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-17
- Target Recruit Count
- 9999
- Registration Number
- NCT07019038
- Locations
- 🇨🇳
Red Blood Cell Diseases Center and Regenerative Medicine Center, Tianjin, Tianjin, China
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Phase 2
Recruiting
- Conditions
- Sever Aplastic AnaemiaElderly (People Aged 65 or More)Immunosuppressive Treatment
- Interventions
- Drug: Dose-attenuated IST and Hetrombopag
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Target Recruit Count
- 65
- Registration Number
- NCT07010237
- Locations
- 🇨🇳
Red Blood Cell Diseases Center, Tianjin, Tianjin, China
The Mutation Profile and Prognosis in AML With IDH1/2 Mutation
Completed
- Conditions
- AML
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-06-04
- Target Recruit Count
- 1015
- Registration Number
- NCT07004816
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 50
- Next
News
No news found